For adults with moderate to severe hidradenitis suppurativa
COSENTYX® (secukinumab) is the first FDA-approved medicine of its kind† to treat adults with moderate to severe hidradenitis suppurativa (HS).
Hidradenitis suppurativa (HS) is a chronic, or long-lasting, inflammatory skin condition. It is thought that an overactive immune system may contribute to inflammation in different areas of the body that can lead to HS symptoms, like bumps and abscesses that can hurt. Living with HS can be a daily challenge.
†COSENTYX targets and blocks IL-17A, a molecule thought to play a role in the inflammation that may contribute to HS symptoms.
Real results. Real relief from HS symptoms.
COSENTYX was proven to help adults with moderate to severe HS find relief at 16 weeks:
At least a 50% reduction in the number of inflammatory bumps and abscesses
No increase in the number of abscesses and/or draining tunnels
In the 2 clinical trials, 41% and 43% of adults taking COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses) achieved at least a 50% reduction in the number of inflammatory bumps and abscesses, with no increase in the number of abscesses and/or draining tunnels at 16 weeks vs 29% and 26% taking placebo.
Since 2015, over 3.7 million COSENTYX prescriptions have been filled†† in the United States.§
COSENTYX has had a well-studied safety profile since its launch in 2015 and has been approved to treat numerous conditions:
2015 — adults with moderate to severe plaque psoriasis
2016 — adults with active ankylosing spondylitis and active psoriatic arthritis
2020 — adults with active non-radiographic axial spondyloarthritis
2021 — children with plaque psoriasis (6 years and older), psoriatic arthritis (2 years and older), and enthesitis-related arthritis (4 years and older)
2023 — adults with moderate to severe hidradenitis suppurativa
††Across all indications combined (not including HS).
§As of March 2023.
How is COSENTYX different?
COSENTYX is the first biologic treatment of its kind to treat HS by specifically targeting and blocking IL-17A, a molecule that is thought to play a role in causing inflammation that may contribute to HS symptoms.
See how COSENTYX takes on HS —from the inside out. Watch a video of how COSENTYX is thought to help adults with HS.
Download our patient brochure to learn more about treating moderate to severe HS in adults with COSENTYX.
Savings & Support
Enroll in our $0 Co-Pay offer and pay as little as $0 through the COSENTYX® Connect Co-Pay Program, if privately insured and otherwise eligible.
COSENTYX® Connect is a free, personalized support program for people taking or considering COSENTYX. Our goal is to make the COSENTYX experience as easy, affordable, and convenient as possible for you. Sign up now and you'll have access to a full range of services, like a dedicated COSENTYX® Connect Team, $0 co-pay,* if eligible, and injection resources.
*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.
FIND A DOCTOR
REAL PEOPLE TAKING COSENTYX® (secukinumab) ARE SEEING REAL RESULTS.
Could you be one of them? Find a dermatologist in your area who has experience treating HS.
MAKE A PLAN
TELL YOUR DERMATOLOGIST HOW YOU REALLY FEEL.
Be real about how you feel with your doctor. Use our Doctor Conversation Starter to help you have a better conversation about how hidradenitis suppurativa affects you.